Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.
Morimoto K, Hamashima R, Yamada T, Yokoyama T, Kobayashi T, Tsuyuguchi K, Kanematsu T, Tamiya N, Tsuji T, Nakamura R, Katayama Y, Nishioka N, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: yokoyama t. Thorac Cancer. 2024 Sep;15(26):1882-1888. doi: 10.1111/1759-7714.15416. Epub 2024 Aug 1. Thorac Cancer. 2024. PMID: 39090758 Free PMC article.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F. Hata A, et al. Among authors: yokoyama t. Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7. Cancer. 2018. PMID: 30192383 Free article. Clinical Trial.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Nakao A, et al. Among authors: yokoyama t. Oncologist. 2019 May;24(5):593-e170. doi: 10.1634/theoncologist.2019-0003. Epub 2019 Jan 16. Oncologist. 2019. PMID: 30651400 Free PMC article. Clinical Trial.
Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Nakao A, et al. Among authors: yokoyama t. J Clin Med. 2020 Jun 5;9(6):1762. doi: 10.3390/jcm9061762. J Clin Med. 2020. PMID: 32517152 Free PMC article.
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group. Harada D, et al. Among authors: yokoyama t. Thorac Cancer. 2021 Mar;12(5):643-649. doi: 10.1111/1759-7714.13825. Epub 2021 Jan 20. Thorac Cancer. 2021. PMID: 33470536 Free PMC article. Clinical Trial.
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Among authors: yokoyama t. J Cancer Res Clin Oncol. 2023 Jun;149(6):2475-2482. doi: 10.1007/s00432-022-04125-8. Epub 2022 Jun 23. J Cancer Res Clin Oncol. 2023. PMID: 35737092
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Among authors: yokoyama t. Thorac Cancer. 2023 Apr;14(11):1004-1011. doi: 10.1111/1759-7714.14836. Epub 2023 Mar 3. Thorac Cancer. 2023. PMID: 36866788 Free PMC article.
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L).
Wakuda K, Yamaguchi H, Kenmotsu H, Fukuda M, Ito K, Tsuchiya-Kawano Y, Tanaka K, Harada T, Nakatani Y, Miura S, Yokoyama T, Nakamura T, Izumi M, Nakamura A, Ikeda S, Takayama K, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. Wakuda K, et al. Among authors: yokoyama t. JTO Clin Res Rep. 2023 Oct 12;4(12):100587. doi: 10.1016/j.jtocrr.2023.100587. eCollection 2023 Dec. JTO Clin Res Rep. 2023. PMID: 38046380 Free PMC article.
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
Morita A, Ichihara E, Inoue K, Fujiwara K, Yokoyama T, Harada D, Ando C, Kano H, Oda N, Tamura T, Ochi N, Kawai H, Inoue M, Hara N, Fujimoto N, Ichikawa H, Oze I, Hotta K, Maeda Y, Kiura K. Morita A, et al. Among authors: yokoyama t. Int J Cancer. 2024 May 1;154(9):1607-1615. doi: 10.1002/ijc.34842. Epub 2024 Jan 9. Int J Cancer. 2024. PMID: 38196128
3,925 results